Efficacy of daratumumab combination regimen in patients with multiple myeloma: A combined analysis of phase III randomized controlled trials

Thura W. Htut; Kyaw Z. Thein; Alastair Lawrie; Jane Tighe; Gavin Preston

doi:10.1002/jha2.46

Efficacy of daratumumab combination regimen in patients with multiple myeloma: A combined analysis of phase III randomized controlled trials

Thura W. Htut^* (Corresponding Author)
, Kyaw Z. Thein
, Alastair Lawrie
, Jane Tighe
, Gavin Preston

^*Corresponding author for this work

University of Texas MD Anderson Cancer Center

Research output: Contribution to journal › Article › peer-review

9 Downloads (Pure)

Abstract

Abstract The use of the CD38 monoclonal antibody daratumumab in combination with standard myeloma chemotherapy regimens has been studied extensively in recent years. We undertook an updated meta-analysis of phase III randomized controlled trials (RCT) to determine the efficacy of daratumumab combination regimens. The relative risk for progression was significantly lower in daratumumab-treated cohorts (HR 0.46, 95% CI 0.38-0.55) and this was consistent across newly diagnosed and relapsed cases. No statistically significant improvement was identified in newly diagnosed patients with high-risk cytogenetics and this group remains a therapeutic challenge.

Original language	English
Pages (from-to)	262-266
Number of pages	5
Journal	eJHaem
Volume	1
Issue number	1
Early online date	23 Jun 2020
DOIs	https://doi.org/10.1002/jha2.46
Publication status	Published - Jul 2020

Bibliographical note

Open Access via the Jis Wiley Agreement

Keywords

daratumumab
meta-analysis
multiple myeloma
phase III randomized controlled trials

Access to Document

10.1002/jha2.46Licence: CC BY

Htut_etal_jha_efficacy_VOR
© 2020 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. https://creativecommons.org/licenses/by/4.0/
Final published version, 858 KBLicence: CC BY

Cite this

@article{2b5a698b4a1c40cb9d089e4da13a4c83,

title = "Efficacy of daratumumab combination regimen in patients with multiple myeloma: A combined analysis of phase III randomized controlled trials",

abstract = "Abstract The use of the CD38 monoclonal antibody daratumumab in combination with standard myeloma chemotherapy regimens has been studied extensively in recent years. We undertook an updated meta-analysis of phase III randomized controlled trials (RCT) to determine the efficacy of daratumumab combination regimens. The relative risk for progression was significantly lower in daratumumab-treated cohorts (HR 0.46, 95\% CI 0.38-0.55) and this was consistent across newly diagnosed and relapsed cases. No statistically significant improvement was identified in newly diagnosed patients with high-risk cytogenetics and this group remains a therapeutic challenge.",

keywords = "daratumumab, meta-analysis, multiple myeloma, phase III randomized controlled trials",

author = "Htut, \{Thura W.\} and Thein, \{Kyaw Z.\} and Alastair Lawrie and Jane Tighe and Gavin Preston",

note = "Open Access via the Jis Wiley Agreement",

year = "2020",

month = jul,

doi = "10.1002/jha2.46",

language = "English",

volume = "1",

pages = "262--266",

journal = "eJHaem",

issn = "2688-6146",

publisher = "John Wiley \& Sons, Ltd",

number = "1",

}

TY - JOUR

T1 - Efficacy of daratumumab combination regimen in patients with multiple myeloma

T2 - A combined analysis of phase III randomized controlled trials

AU - Htut, Thura W.

AU - Thein, Kyaw Z.

AU - Lawrie, Alastair

AU - Tighe, Jane

AU - Preston, Gavin

N1 - Open Access via the Jis Wiley Agreement

PY - 2020/7

Y1 - 2020/7

N2 - Abstract The use of the CD38 monoclonal antibody daratumumab in combination with standard myeloma chemotherapy regimens has been studied extensively in recent years. We undertook an updated meta-analysis of phase III randomized controlled trials (RCT) to determine the efficacy of daratumumab combination regimens. The relative risk for progression was significantly lower in daratumumab-treated cohorts (HR 0.46, 95% CI 0.38-0.55) and this was consistent across newly diagnosed and relapsed cases. No statistically significant improvement was identified in newly diagnosed patients with high-risk cytogenetics and this group remains a therapeutic challenge.

AB - Abstract The use of the CD38 monoclonal antibody daratumumab in combination with standard myeloma chemotherapy regimens has been studied extensively in recent years. We undertook an updated meta-analysis of phase III randomized controlled trials (RCT) to determine the efficacy of daratumumab combination regimens. The relative risk for progression was significantly lower in daratumumab-treated cohorts (HR 0.46, 95% CI 0.38-0.55) and this was consistent across newly diagnosed and relapsed cases. No statistically significant improvement was identified in newly diagnosed patients with high-risk cytogenetics and this group remains a therapeutic challenge.

KW - daratumumab

KW - meta-analysis

KW - multiple myeloma

KW - phase III randomized controlled trials

U2 - 10.1002/jha2.46

DO - 10.1002/jha2.46

M3 - Article

SN - 2688-6146

VL - 1

SP - 262

EP - 266

JO - eJHaem

JF - eJHaem

IS - 1

ER -

Efficacy of daratumumab combination regimen in patients with multiple myeloma: A combined analysis of phase III randomized controlled trials

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this